Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene
Now that their Enbrel franchise appears to be secure from copycat interlopers, Amgen is going for a sure thing on the deal side to bolster its revenue projections.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
